Acute Liver Failure Treatment & Management
- Author: Gagan K Sood, MD; Chief Editor: BS Anand, MD more...
The most important aspect of treatment in patients with acute liver failure is to provide good intensive care support.[1, 2, 3, 4] Patients with grade II encephalopathy should be transferred to the intensive care unit (ICU) for monitoring. As encephalopathy progresses, protection of the airway becomes increasingly important.
Most patients with acute liver failure tend to develop some degree of circulatory dysfunction. Careful attention should be paid to fluid management and hemodynamics. Monitoring of metabolic parameters, surveillance for infection, maintenance of nutrition, and prompt recognition of gastrointestinal bleeding are crucial.
Coagulation parameters, complete blood cell count, and metabolic panel should be checked frequently. Serum aminotransferases and bilirubin are generally measured daily to follow the course of the disease.
As patients with fulminant hepatic failure drift deeper into coma, the ability to protect their airway from aspiration decreases. Patients who are in stage III coma should have a nasogastric tube (NGT) inserted for stomach decompression. When patients progress to stage III coma, intubation should be performed.
Short-acting benzodiazepines in low doses (eg, midazolam, 2-3 mg) may be used before intubation, or propofol (50 mcg/kg/min) may be initiated before intubation and continued as an infusion. Propofol is also known to decrease the cerebral blood flow and intracranial hypertension (ICH). It may be advisable to use endotracheal lidocaine before endotracheal suctioning.
Management of Encephalopathy and Cerebral Edema
Patients with grade I encephalopathy may sometimes be safely managed in a medicine ward. Frequent mental status checks should be performed, and transfer to an ICU is warranted with progression to grade II encephalopathy.
Sedation should be avoided if possible. Unmanageable agitation may be treated with short-acting benzodiazepines in low doses.
Patients should be positioned with the head elevated at 30°. Efforts should be made to avoid patient stimulation. Maneuvers that cause straining or, in particular, Valsalva-like movements may increase intracranial pressure (ICP).
There is increasing evidence that ammonia may play a pathogenic role in the development of cerebral edema. Reducing elevated ammonia levels with enteral administration of lactulose might help prevent or treat cerebral edema. In the late stages of encephalopathy, to reduce the risk of aspiration, avoid providing lactulose by mouth or nasogastric tube in the absence of endotracheal intubation.
The occurrence of cerebral edema and ICH in patients with acute liver failure is related to the severity of encephalopathy. Cerebral edema is seldom observed in patients with grades I-II encephalopathy. The risk of edema increases to 25-35% with progression to grade III and increases to 65-75% (or more) in patients reaching grade IV coma.
Patients in the advanced stages of encephalopathy require close follow-up care. Monitoring and management of hemodynamic and renal parameters, as well as glucose, electrolytes, and acid/base status, become critical. Frequent neurologic evaluation for signs of elevated ICP should be conducted.
Intracranial pressure monitoring
In patients with grade III or IV encephalopathy, consider placement of an ICP monitor. ICP monitoring helps in the early recognition of cerebral edema.
The clinical signs of elevated ICP, including hypertension, bradycardia, and irregular respirations (Cushing triad), are not uniformly present; these and other neurologic changes, such as papillary dilatation or signs of decerebration, are typically evident only late in the course. CT scanning of the brain does not reliably detect edema, especially in the early stages.
The primary purpose of ICP monitoring is to detect elevations in ICP and reductions in cerebral perfusion pressure (CPP; calculated as mean arterial pressure [MAP] minus ICP) so that interventions can be made to prevent herniation while preserving brain perfusion. The ultimate goal of such measures is to maintain neurologic integrity and to prolong survival while awaiting the receipt of a donor organ or recovery of sufficient functioning hepatocyte mass. Additionally, refractory ICH and/or decreased CPP are considered contraindications to liver transplantation in many centers.
If an ICP monitor is placed, ICP should be maintained below 20-25 mm Hg, if possible, with CPP maintained above 50-60 mm Hg. Support of systemic blood pressure may be required to maintain adequate CPP.
Management of intracranial hypertension
ICH is managed initially with the use of mannitol. Osmotic diuresis with IV mannitol is effective in the short term in decreasing cerebral edema. Administration of IV mannitol (in a bolus dose of 0.5-1 g/kg or 50-100 g) is recommended to treat ICH in acute liver failure. The dose may be repeated once or twice, as needed, provided that serum osmolality has not exceeded 320 mOsm/L. Volume overload is a risk with mannitol use in patients with renal impairment and may necessitate the use of dialysis to remove excess fluid.
If life-threatening ICH is not controlled with mannitol infusion and other general management as outlined above, hyperventilation may be instituted temporarily in an attempt to acutely lower the ICP and to prevent impending herniation. Hyperventilation to reduce the partial pressure of carbon dioxide in the blood (PaCO2) to 25-30 mm Hg can quickly lower ICP via vasoconstriction, causing decreased cerebral blood flow, but this effect is short-lived.
Other therapies used to decrease ICH but not routinely recommended may be considered in refractory ICH. These include hypertonic saline, barbiturates, and hypothermia.
A controlled trial of administration of 30% hypertonic saline, 5-20 mL/h, to maintain serum sodium levels of 145-155 mmol/L in patients with acute liver failure and severe encephalopathy suggested that induction and maintenance of hypernatremia may be used to prevent the rise in ICP values.
Barbiturate agents (thiopental or pentobarbital) may also be considered when severe ICH does not respond to other measures; administration has been shown to effectively decrease ICP. Significant systemic hypotension frequently limits their use and may necessitate additional measures to maintain adequate mean arterial pressure. Doses of barbiturates for ICH are as follows:
Thiopental: 5-10 mg/kg loading dose followed by 3-5 mg/kg IV infusion
Pentobarbital: 3-5 mg/kg IV loading dose followed by 1-3 mg/kg/h infusion
Moderate hypothermia (32-34°C) may prevent or control ICH in patients with acute liver failure. An external cooling blanket may be used to achieve this goal. Potential deleterious effects of hypothermia include increased risk of infection, coagulation disturbance, and cardiac arrhythmias.
Hemodynamic derangements consistent with multiple organ failure occur in acute liver failure. Hypotension (ie, systolic blood pressure < 80 mm Hg) may be present in 15% of patients. Most patients will require fluid resuscitation on admission. Intravascular volume deficits may be present on admission due to decreased oral intake or gastrointestinal blood loss.
Hemodynamic derangement resembles that of sepsis or cirrhosis with hepatorenal syndrome (low systemic vascular resistance [SVR] with normal or increased cardiac output). An arterial line should be placed for continuous blood pressure monitoring.
A Swan-Ganz catheter should be placed, and fluid replacement with colloid albumin should be guided by the filling pressure. If needed, dopamine or norepinephrine can be used to correct hypotension.
Management of Coagulopathy
In the absence of bleeding, it is usually not necessary to correct clotting abnormalities with fresh frozen plasma (FFP). The exception is when an invasive procedure is planned or in the presence of profound coagulopathy (INR >7).
Prothrombin time (PT) and partial thromboplastin time (PTT) become prolonged when plasma coagulation components are diluted to less than 30%, and abnormal bleeding occurs when they are less than 17%. One unit of FFP increases the coagulation factor by 5%; 2 units increase it by 10%. An FFP infusion of 15 mL/kg of body weight or 4 units will correct the deficiency. If the fibrinogen level is very low (< 80 mg/dL), consider administering cryoprecipitate.
Recombinant factor VIIa may be used in patients whose condition is nonresponsive to FFP. It is used in a dose of 4 µg/kg IV push over 2-5 minutes. PT is normalized in 20 minutes and remains normalized for 3-4 hours.
Platelet transfusions are not used until the count is less than 10,000/µL or if an invasive procedure is being done and the platelet count is less than 50,000/µL. Six to 8 units of random donor platelets (1 random donor unit platelet/10 kg) will increase the platelet count to greater than 50,000/µL. The platelet count should be checked after 1 hour and 24 hours. Transfused platelets survive 3-5 days.
Management of Acetaminophen Toxicity
Treat acetaminophen (paracetamol, APAP) overdose with N-acetylcysteine (NAC). Researchers theorize that this antidote works by a number of protective mechanisms. Early after an overdose, NAC prevents the formation and accumulation of N -acetyl-p-benzoquinone imine (NAPQI), a free radical that binds to intracellular proteins, nonspecifically resulting in toxicity.
NAC increases glutathione stores, combines directly with NAPQI as a glutathione substitute, and enhances sulfate conjugation. NAC also functions as an anti-inflammatory and antioxidant and has positive inotropic and vasodilating effects, which improve the microcirculatory blood flow and oxygen delivery to tissues. These latter effects decrease morbidity and mortality once hepatotoxicity is well established.
The protective effect of NAC is greatest when administered within 8 hours of ingestion; however, when indicated, administer regardless of the time since the overdose. Therapy with NAC has been shown to decrease mortality in late-presenting patients with fulminant hepatic failure (in the absence of acetaminophen in the serum).
If patients present within 4 hours of overdosing on acetaminophen, give activated charcoal just prior to starting NAC.
Never administer aminoglycosides or nonsteroidal anti-inflammatory drugs (NSAIDs) to patients with acetaminophen hepatotoxicity, because the potential for nephrotoxicity is exaggerated greatly in this setting.
Treat Amanita phalloides mushroom intoxication with IV penicillin G, even though its mode of action is unclear. Silibinin, a water-soluble derivative of silymarin, may be administered orally, and oral charcoal may be helpful by binding the mushroom toxin.
Liver transplantation is the definitive treatment in liver failure, but a detailed discussion is beyond the scope of this article. For more information on liver transplantation, see the Medscape articles Liver Transplants and Pediatric Liver Transplantation. The American Association for the Study of Liver Diseases has produced guidelines on the evaluation of patients for liver transplantation.[34, 35] Preoperative management is emphasized in this section.
In selected patients for whom no allograft is immediately available, consider support with a bioartificial liver. This is a short-term measure that only leads to survival if the liver spontaneously recovers or is replaced.[5, 6, 7, 8]
Artificial liver support systems can be divided into 2 major categories: biologic (bioartificial) and nonbiologic.
The bioartificial liver is composed of a dialysis cartridge with mammalian or porcine hepatocytes filling the extracapillary spaces. These devices have undergone controlled trials. One multicenter trial reported improved short-term survival for a subgroup of patients with acute liver failure who were treated with a porcine hepatocyte-based artificial liver.
Nonbiologic extracorporeal liver support systems, such as hemodialysis, hemofiltration, charcoal hemoperfusion, plasmapheresis, and exchange transfusions, have been used; however, no controlled study has shown long-term benefit.
These modalities permit temporary liver support until a suitable donor liver is found. Although extracorporeal hemoperfusion of charcoal and other inert substances provide some measure of excretory function, this technique provides no synthetic capacity.
Among the liver support systems currently available, albumin dialysis using the molecular adsorbent recirculating system (MARS) is the one that has been most extensively investigated. In this device, blood is dialyzed across an albumin-impregnated membrane against 20% albumin. Charcoal and anion exchange resin columns in the circuit cleanse and regenerate the albumin dialysate. Clinical studies have shown that this system improves hyperbilirubinemia and encephalopathy.
Two other systems based on the removal of albumin bound toxins—the Prometheus, using the principle of fractionated plasma separation and adsorption (FPSA), and the single pass albumin dialysis (SPAD)—are also undergoing clinical studies for acute liver failure.
Currently available liver support systems are not routinely recommended outside of clinical trials. In the future, hepatocyte transplantation, which has shown dramatic results in animal models of acute liver failure, may provide long-term support, but this approach remains investigational.
Patients with acute liver failure are, by necessity, on nothing by mouth (NPO) status. They may require large amounts of IV glucose to avoid hypoglycemia.
When enteral feeding via a feeding tube is not feasible (eg, as in a patient with paralytic ileus), institute total parenteral nutrition (TPN). (See also Nutritional Requirements of Adults Before Transplantation and Nutritional Requirements of Children Prior to Transplantation.) Restricting protein (amino acids) to 0.6 g/kg body weight per day was previously routine in the setting of hepatic encephalopathy. However, this may not be necessary.
Long Term Monitoring
Bed rest is recommended.
Managing fulminant hepatic failure is a team effort. Consultations with specialists in intensive care, gastroenterology, infectious diseases, hematology, neurology, neurosurgery, and transplantation surgery may be needed to address the myriad complex issues that can confront the medical staff.
[Guideline] Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005 May. 41(5):1179-97. [Medline].
Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007 Nov. 35(11):2498-508. [Medline].
Bernal W. Intensive care support therapy. Liver Transpl. 2003 Sep. 9(9):S15-7. [Medline].
Jalan R. Acute liver failure: current management and future prospects. J Hepatol. 2005. 42 Suppl(1):S115-23. [Medline].
Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs. 1994 May. 18(5):390-6. [Medline].
Hughes RD, Williams R. Use of bioartificial and artificial liver support devices. Semin Liver Dis. 1996 Nov. 16(4):435-44. [Medline].
Nyberg SL, Misra SP. Hepatocyte liver-assist systems--a clinical update. Mayo Clin Proc. 1998 Aug. 73(8):765-71. [Medline].
Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004 May. 239(5):660-7; discussion 667-70. [Medline]. [Full Text].
Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology. 2004 Nov. 127(5):1338-46. [Medline].
Jiang W, Desjardins P, Butterworth RF. Hypothermia attenuates oxidative/nitrosative stress, encephalopathy and brain edema in acute (ischemic) liver failure. Neurochem Int. 2009 Jul-Aug. 55(1-3):124-8. [Medline].
Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology. 1995 Jan. 21(1):240-52. [Medline].
Lee WM, Schiodt FV. Fulminant hepatic failure. In: Schiff ER, Sorrell, MF, Maddrey WC, eds. Schiff's Diseases of the Liver. 8th ed. Baltimore: Md: Lippincott Williams & Wilkins; 1999.
Lidofsky SD, Bass NM, Prager MC, Washington DE, Read AE, Wright TL, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology. 1992 Jul. 16(1):1-7. [Medline].
Detry O, Arkadopoulos N, Ting P, Kahaku E, Margulies J, Arnaout W, et al. Intracranial pressure during liver transplantation for fulminant hepatic failure. Transplantation. 1999 Mar 15. 67(5):767-70. [Medline].
Schiødt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med. 1997 Oct 16. 337(16):1112-7. [Medline].
Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005 Dec. 42(6):1364-72. [Medline].
Davern TJ 2nd, James LP, Hinson JA, Polson J, Larson AM, Fontana RJ, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology. 2006 Mar. 130(3):687-94. [Medline].
Khandelwal N, James LP, Sanders C, Larson AM, Lee WM. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011 Feb. 53(2):567-76. [Medline].
Paterson JM, Mamdani MM, Manno M, Juurlink DN. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012 Aug 13. [Medline].
Notes from the field: acute hepatitis and liver failure following the use of a dietary supplement intended for weight loss or muscle building - may-october 2013. MMWR Morb Mortal Wkly Rep. 2013 Oct 11. 62(40):817-9. [Medline]. [Full Text].
Hand L. CDC: supplement linked to hepatitis, liver failure. Medscape Medical News. October 15, 2013. Available at http://www.medscape.com/viewarticle/812581. Accessed: October 22, 2013.
Lo Re V 3rd, Haynes K, Forde KA, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy's law and a new prognostic model. Clin Gastroenterol Hepatol. 2015 Dec. 13 (13):2360-8. [Medline].
Klein AS, Hart J, Brems JJ, Goldstein L, Lewin K, Busuttil RW. Amanita poisoning: treatment and the role of liver transplantation. Am J Med. 1989 Feb. 86(2):187-93. [Medline].
Hoyer DP, Munteanu M, Canbay A, et al. Liver transplantation for acute liver failure: are there thresholds not to be crossed?. Transpl Int. 2014 Jun. 27 (6):625-33. [Medline].
O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989 Aug. 97(2):439-45. [Medline].
Lee WM, Galbraith RM, Watt GH, Hughes RD, McIntire DD, Hoffman BJ, et al. Predicting survival in fulminant hepatic failure using serum Gc protein concentrations. Hepatology. 1995 Jan. 21(1):101-5. [Medline].
Schiødt FV, Rossaro L, Stravitz RT, Shakil AO, Chung RT, Lee WM. Gc-globulin and prognosis in acute liver failure. Liver Transpl. 2005 Oct. 11(10):1223-7. [Medline].
[Guideline] Kelly JC. Drug-Induced Liver Injury Guidelines Released by ACG. Medscape Medical News. Jun 18 2014. [Full Text].
[Guideline] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014 Jun 17. [Medline].
Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Casewell M, et al. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol. 1991 Jan. 12(1):1-9. [Medline].
Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology. 2004 Feb. 39(2):464-70. [Medline].
Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis. 1996 Nov. 16(4):403-14. [Medline].
Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2015 Dec 25. 1-20. [Medline].
[Guideline] Murray KF, Carithers RL Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005 Jun. 41(6):1407-32. [Medline].
AASLD position paper: the management of acute liver failure. Private Nonprofit Research Organization. American Association for the Study of Liver Diseases - Private Nonprofit Research Organization. 2005 May. 36(1):19 pages.
ClinicalTrials.gov. The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure. Available at http://clinicaltrials.gov/ct2/show/NCT00655304.
Fontana RJ, Ellerbe C, Durkalski VE, et al; for the US Acute Liver Failure Study Group. Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. Liver Int. 2015 Feb. 35 (2):370-80. [Medline].
Fairfield C, Penninga L, Powell J, Harrison EM, Wigmore SJ. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients. Cochrane Database Syst Rev. 2015 Dec 15. 12:CD007606. [Medline].
|Grade||Level of Consciousness||Personality and Intellect||Neurologic Signs||Electroencephalogram (EEG) Abnormalities|
|Subclinical||Normal||Normal||Abnormalities only on psychometric testing||None|
|1||Day/night sleep reversal, restlessness||Forgetfulness, mild confusion, agitation, irritability||Tremor, apraxia, incoordination, impaired handwriting||Triphasic waves (5 Hz)|
|2||Lethargy, slowed responses||Disorientation to time, loss of inhibition, inappropriate behavior||Asterixis, dysarthria, ataxia, hypoactive reflexes||Triphasic waves (5 Hz)|
|3||Somnolence, confusion||Disorientation to place, aggressive behavior||Asterixis, muscular rigidity, Babinski signs, hyperactive reflexes||Triphasic waves (5 Hz)|
|4||Coma||None||Decerebration||Delta/slow wave activity|